Literature DB >> 34078311

Tracking the dropout patients of neoadjuvant chemotherapy with locally advanced oral cavity cancer.

Jin-Ye Fu1, Chen-Ping Zhang2, Zhi-Yuan Zhang3.   

Abstract

BACKGROUND: Patients with locally advanced oral cavity cancer sometimes stopped treatment after neoadjuvant chemotherapy. There are no guidelines of the management for these patients. Before designing clinical trials, we conducted this study to investigate their characteristics, reasons of dropout, and the follow-up information.
METHODS: Medical records were consecutively reviewed of patients with locally advanced oral cavity cancer who underwent neoadjuvant chemotherapy from Jan 2017 to Dec 2019.Variables were compared between patients stopped treating after chemotherapy and completed treatments by student t-test and Chi-square test. Logistic regression model was used to calculate the odd rations of potential predictors of dropout. The dropout patients were followed up for reasons and results of their decision.
RESULTS: A total of 171 patients were included with 23 not undergoing surgery after chemotherapy. The odd ratios of age over 65 and single marital status were 3.11 (95%CI: 1.1, 8.7) and 4.935 (95%CI: 1.5, 16.1), respectively, for the dropout. The median survival of patients without surgery was 7.4 months. Believing that chemotherapy would be effective and being afraid of the consequence of surgery were the main reasons of refusing surgery.
CONCLUSIONS: The prognosis was poor of these dropout patients. Symptom relief and fear of surgery were the reasons of dropout. Age and marital status affected their decision. Clinical trials are needed to be designed for these patients.

Entities:  

Keywords:  Decision making; Drop-out patients; Median survival; Neoadjuvant chemotherapy; Nonsurgical treatment; Oral cancer

Year:  2021        PMID: 34078311     DOI: 10.1186/s12885-021-08420-4

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  25 in total

1.  Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.

Authors:  Aaron W Pederson; Joseph K Salama; Mary Ellen Witt; Kerstin M Stenson; Elizabeth A Blair; Everett E Vokes; Daniel J Haraf
Journal:  Am J Clin Oncol       Date:  2011-08       Impact factor: 2.339

2.  Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience.

Authors:  Corey C Foster; James M Melotek; Ryan J Brisson; Tanguy Y Seiwert; Ezra E W Cohen; Kerstin M Stenson; Elizabeth A Blair; Louis Portugal; Zhen Gooi; Nishant Agrawal; Everett E Vokes; Daniel J Haraf
Journal:  Oral Oncol       Date:  2018-03-16       Impact factor: 5.337

3.  Differences in Survival With Surgery and Postoperative Radiotherapy Compared With Definitive Chemoradiotherapy for Oral Cavity Cancer: A National Cancer Database Analysis.

Authors:  Michael T Spiotto; Gina Jefferson; Barry Wenig; Michael Markiewicz; Ralph R Weichselbaum; Matthew Koshy
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-07-01       Impact factor: 6.223

4.  Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience.

Authors:  Eli D Scher; Paul B Romesser; Christine Chen; Felix Ho; Yen Wuu; Eric J Sherman; Matthew G Fury; Richard J Wong; Sean McBride; Nancy Y Lee; Nadeem Riaz
Journal:  Oral Oncol       Date:  2015-05-07       Impact factor: 5.337

5.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

6.  Chemoradiation for patients with advanced oral cavity cancer.

Authors:  Kerstin M Stenson; Rangesh Kunnavakkam; Ezra E W Cohen; Louis D Portugal; Elizabeth Blair; Daniel J Haraf; Joseph Salama; Everett E Vokes
Journal:  Laryngoscope       Date:  2010-01       Impact factor: 3.325

7.  Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy.

Authors:  Ezra E W Cohen; Joshua Baru; Dezheng Huo; Daniel J Haraf; Maureen Crowley; Mary Ellyn Witt; Elizabeth A Blair; Ralph R Weichselbaum; Fred Rosen; Everett E Vokes; Kerstin Stenson
Journal:  Head Neck       Date:  2009-08       Impact factor: 3.147

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).

Authors:  J Inhestern; H Schmalenberg; A Dietz; N Rotter; G Maschmeyer; M Jungehülsing; C Grosse-Thie; T Kuhnt; M Görner; H Sudhoff; C Wittekindt; O Guntinas-Lichius
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

10.  Surgery and adjuvant radiotherapy vs concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison.

Authors:  K-C Soo; E-H Tan; J Wee; D Lim; B-C Tai; M-L Khoo; C Goh; S-S Leong; T Tan; K-W Fong; P Lu; A See; D Machin
Journal:  Br J Cancer       Date:  2005-08-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.